Amphastar Pharmaceuticals AMPH Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's accounts receivable?
- Amphastar Pharmaceuticals (AMPH) reported accounts receivable of $147.85M in Q1 2026.
- How has Amphastar Pharmaceuticals's accounts receivable changed year-over-year?
- Amphastar Pharmaceuticals's accounts receivable increased by 2.2% year-over-year, from $144.64M to $147.85M.
- What is the long-term trend for Amphastar Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's accounts receivable has grown at a 16.8% compound annual growth rate (CAGR), from $66.01M to $143.56M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.